Zydus Cadila said ZYIL1 will bridge a critical unmet healthcare need in several inflammatory diseases including COVID-19
Drug firm Zydus Cadila on Tuesday said it has filed the investigational new drug (IND) application for ZYIL1, positioned for management of critically ill COVID-19 patients.“Following up on its initiatives to fight COVID-19 with diagnostics, vaccines and therapeutics, the company is now focussing on cutting edge research to bring targeted therapies… it has filed the IND application of ZYIL1, a novel oral small molecule,” the company said in a regulatory filing.Zydus Cadila said ZYIL1 will bridge a critical unmet healthcare need in several inflammatory diseases including the current pandemic of COVID-19 and address complications caused by chronic and uncontrolled inflammation.Also read | Supreme Court to seek government response on plea on COVID-19 drugsThe company said it has completed all IND enabling preclinical studies and has filed the IND application to advance this drug candidate towards the clinic.Zydus Cadila said ZYIL1, has demonstrated promising efficacy in a number of validated pre-clinical models of Inflammatory Bowel Disease (IBD), Multiple Sclerosis (MS), Sepsis and acute lung injury models of Acute Respiratory Distress Syndrome (ARDS).Shares of Cadila Healthcare were trading 7.88% higher at ₹442.45 apiece on BSE.
A letter from the Editor
Dear subscriber,Thank you!Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.Suresh Nambath